|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | 0.00% |
| 2022 | Sanofi profit gain beats market view on bestseller drug Dupixent | RE |
| 2022 | Sanofi to float drug ingredients manufacturing business on May 6 | RE |
Epic Corp. announced earnings results for the year ended September 30, 2013. For the period, the company earned $0.17 per share of issued and outstanding common stock, has a book value of $0.67 per share, a return on equity of 176%.
The company has earned $1,798,239 with 10,669,294 shares issued and outstanding, its total assets equal $8,343,854, and its book value is $7,103,897.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 20 | |
| +17.23% | 7.07B | |
| -29.61% | 819M | |
| -34.41% | 662M | |
| +100.00% | 542M | |
| +188.97% | 424M | |
| -52.94% | 328M | |
| -10.17% | 127M | |
| -.--% | 118M | |
| -15.11% | 102M |
EPIC CORP. 
